Novel allosteric antagonists shed light on mglu5 receptors and CNS disorders

Trends in Pharmacological Sciences

Volumn 22, Issue 7, 2001, Pages 331-337

  Spooren, Will P J M ^a   Gasparini, Fabrizio ^a   Salt, Thomas E ^b   Kuhn, Rainer ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 CHLORO 5 HYDROXYPHENYLGLYCINE; 2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 2,5 DIHYDROXYPHENYLGLYCINE; 6 METHYL 2 PHENYLAZO 3 PYRIDINOL; [1 AMINO 1 CARBOXY 2 (9H THIOXANTHEN 9 YL)ETHYL]CYCLOBUTANECARBOXYLIC ACID; [1 AMINO 1 CARBOXY 2 (9H THIOXANTHEN 9 YL)ETHYL]CYCLOPROPANECARBOXYLIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; HALOPERIDOL; INOSITOL PHOSPHATE; IONOTROPIC RECEPTOR; LEVODOPA; LIGAND; LY 393675; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; QUISQUALIC ACID; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANXIETY NEUROSIS; BINDING SITE; BLOOD BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICAL STRUCTURE; CHRONIC PAIN; CLONING; COMPETITIVE INHIBITION; CONDITIONED REFLEX; DEPRESSION; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; EPILEPSY; GENE EXPRESSION; HUMAN; IC 50; IONTOPHORESIS; NERVOUS SYSTEM FUNCTION; NEUROPROTECTION; NOCICEPTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; REVIEW;

ALLOSTERIC REGULATION; ANIMALS; ANXIETY; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; DEPRESSION; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; NEURONS, AFFERENT; PAIN; PARKINSON DISEASE; PYRIDINES; RATS; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 0035397917     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01694-1     Document Type: Review

References (28)

1. Pharmacology and functions of metabotropic glutamate receptors
2. Cellular localization of a metabotropic glutamate receptor in rat brain
3. Metabotropic glutamate receptors - Immunocytochemical and in situ hybridization analysis
4. Pharmacological agents acting at subtypes of metabotropic glutamate receptors
5. A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices
6. SIB-1757 and SIB-1893: Selective, noncompetitive antagonists of metabotropic glutamate receptor type 5 (mGluR5)
7. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist
8. Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism
9. Synaptic activation of the group I metabotropic glutamate receptor mGlu1 on the thalamocortical neurons of the rat dorsal lateral geniculate nucleus in vitro
10. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus
11. Contributions of mGlu1 and mGlu5 receptors to interactions with N-methyl-D-aspartate receptor-mediated responses and nociceptive sensory responses of rat thalamic neurons
12. (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but not mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus
13. Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems
14. Pharmacology of metabotropic glutamate receptor-mediated enhancement of responses to excitatory and inhibitory amino acids on rat spinal neurones in vivo
15. Potentiation of NMDA and AMPA responses by the specific mGluR5 agonist CHPG in spinal cord motoneurons
16. Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5
17. The function of metabotropic excitatory amino acid receptors in synaptic transmission in the thalamus: Studies with novel phenylglycine antagonists
18. Potential anxiolytic and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist
19. Anxiolytic-like effects of group I metabotropic antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) in rats
20. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats
21. Injections of the metabotropic glutamate receptor antagonist MPEP into the lateral amygdala prevent acquisition of conditioned fear in rats
22. 5) antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) in rodents
23. Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893)
24. Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective
25. mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors
26. Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats
27. Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain
28. mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia